BioNTech Results Presentation Deck

BNT211: Phase 1/2 trial evaluating next Generation CAR-T Targeting Claudin-6 with CARVac in Solid Tumors CAR-T cell therapy + CARVac RNA Vaccine to amplify CAR-T cell in vivo BNT211 CAR Structure ● ● ● 24 New 2nd generation CAR directed against CLDN6, a new highly cancer cell specific carcino-embryonic antigen CLDN6 is expressed in multiple solid cancers with high medical need tumor types CARVac drives in vivo expansion, persistence and efficacy of CAR-T Patients with CLDN6-positive relapsed or refractory advanced solid tumors (up to 36 patients) .. High CLDN6 expression extracellular intracellular aCLDN6 scFv CD8 hinge 4-1BB CD32 Part 1 CLDN6 CAR-T dose escalation (3 dose levels) Part 2 CLDN6 CAR-T + CLDN6 CARVac dose escalation RP2D CLDN6 not present in healthy tissues 0 CLDN6 expressed in multiple cancers Ovarian Part 3 Expansion Cohorts Ovarian Cancer Testicular Cancer Endometrial Cancer ● ● ● ● ● Testicular ● Lung Cancer Gastric Cancer Tumors NOS CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; RP2D, recommended Phase 2 dose; NOS, not otherwise specified Reinhard K, et al. Science 2020; 367:446-453 Lung BIONTECH

View entire presentation